Bioentrepreneurship Biotechnology Synthetic Biology

Top 10 CRISPR Companies leveraging Gene Editing Technologies!

CRISPR companies

Since the past few years, the term “CRISPR” is constantly creating a buzz among various scientific and non-scientific communities. CRISPR is the most accurate, efficient, fast and cheapest gene-editing tool that allows scientists to more precisely than ever before edit or modifies the genome of almost any organism.

Explore More: What Is CRISPR Cas9?

Here are some of the famous CRISPR companies and startups that succeeded in bringing CRISPR technology on a whole new commercial level;

1. Editas Medicine

Editas Medicine
Editas Medicine net worth as of April 17, 2019, is $1.34B
  • Year founded: 2013
  • Founders:  Feng Zhang, J.Keith, Jennifer A. Doudna
  • Headquarters: Cambridge, Massachusetts, USA.
  • Target Area: Biotechnology, Genetics, Health Care, Medical

Editas aims to develop therapies based on CRISPR–Cas9 gene editing technology. They have successfully developed drugs against Leber’s congenital amaurosis. And have been given approval by the FDA for a clinical trial.

The company’s mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Moreover, the company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies. Also, essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.

2. CRISPR Therapeutics



CRISPR Therapeutics net worth as of April 17, 2019, is $2.04B

  • Year founded: 2013
  • Founders: Chad Cowen, Craig Mello, Daniel Anderson, Emmanuelle Charpentier, Matthew Porteus, Rodger Novak, Shaun Foy.
  • Headquarters: Zug, Switzerland
  • Target Area: Biopharma, Biotechnology, Genetics, Medical

CRISPR Therapeutics aims are to develop transformative gene-based medicines for patients with serious diseases. Their therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing technology called CRISPR/Cas9.

Moreover, they are also targeting cancer and genetic disorders. Recently FDA approved their CRISPR therapy called CTX101 for treating Beta-thalassemia and sickle cell anemia.

3. Intellia Therapeutics

Intellia Therapeutics

Intellia Therapeutics net worth as of April 17, 2019, is $0.79B.

  • Year founded: 2014
  • Founders: Andy May, Derrick Rossi, Erik Sontheimer, Jennifer A. Doudna, Luciano Marraffini, Nessan Bermingham, Rachel E. Haurwitz, Rodolphe Barrangou.
  • HeadquartersCambridge, Massachusetts, USA.
  • Target area: Biotechnology, Genetics, Health Care, Medical

Intellia Therapeutics focuses on the development of therapeutics utilizing a gene editing tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis. Also, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

This company is advancing a broad pipeline toward clinical development, including ex vivo, and in vivo approaches.

4. Caribou Biosciences


Net Worth of Caribou Biosciences, Inc. is at least $79.5 Million dollars as of January 2018

  • Year founded: 2011
  • Headquarters: Berkeley, California, USA.
  • Founders: James Berger, Jennifer A. Doudna, Martin Jinek, Rachel E. Haurwitz.
  • Target area: Biopharma, Biotechnology, Genetics, Health Care

Caribou Biosciences is considered one of the pioneers in using CRISPR technology. They develop cellular engineering and analysis solutions based on CRISPR-Cas9 technology platform. The company offers CRISPR-Cas gene editing technology with applications in human and animal therapeutics. Moreover, new disease models, genomics, bioproduction cell lines, and fermentation strains, and plants with enhanced traits.

5. Ligandal Inc.

Ligandal CRISPR


Their revenue is $1.8M

  • Year founded: 2013
  • Headquarters: San Francisco Bay area, California, USA.
  • Founders: Andre Watson, Christian foster.
  • Target area: Biotechnology, Genetics, Nanotechnology

Ligandal Inc focuses on enabling gene therapy on a global scale. The company mission is to cure diseases and enable precision medicine through next-generation nanoscale delivery solutions. Uses the power of ligands – molecules that bind with specific other molecules – as well as a breakthrough nanomedicine platform to target the precise molecular ‘zip codes’ (receptors) of cells and their nuclei.

6. Horizon Discovery Group

Horizon Discovery Group

The net worth of the Horizon discovery group as of 2018 is $49.52 million.

  • Year founded: 2007
  • Headquarters:  Waterbeach, United Kingdom.
  • Founders: Alberto Bardelli, Chris Torrance.
  • Target areas: Biopharm, Biotechnology, Genetics, Health Diagnostics. 

Horizon is a world-leading gene editing company that designs & engineers genetically-modified cells, applying them to advance human health. Their main focuses are to utilize CRISPR technology to edit cells and organisms which later uses in various health-related sectors.

The Company’s gene editing and gene modulation platform can alter almost any DNA sequence or RNA transcription. Moreover, they have generated a catalog of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer.

7. Mammoth Biosciences

Mammoth Biosciences

The net worth of mammoth biosciences as of 2018 is $23 Million

  • Year founded: 2017
  • Headquarters: San Francisco Bay area, California, USA
  • Founders: Ashley Tehranchi, Janice Chen, Jennifer A. Doudna, Lucas Harrington, Trevor Martin
  • Target areas: Bioinformatics, Biotechnology, Genetics, Health Diagnostics, Life Science

The company is co-founded by Jennifer Doudna, who is considered the pioneer of the CRISPR/Cas gene-editing tool. The startup uses CRISPR techniques to detect and diagnose diseases.

Mammoth Biosciences utilizes CRISPR gene recognition ability, but it is modified in a way that instead of cleaving the recognized sequence, it binds with it and releases a reporter molecule. That reports the presence of a foreign genome. It is a kind of CRISPR-based platform for disease detection.

8. Synthego

Synthego CRISPR

Estimated revenue for 2018 is $13 million

  • Year founded:  2012
  • Headquarters: Silicon Valley, California, USA.
  • Founders: Alex Pesch, Michael Dabrowski, Paul Dabrowski
  • Target areas: Biotechnology, Genetics, Industrial Automation, Innovation Management, Software

Founded by former SpaceX engineers, Synthego is a leading provider of synthetic RNA solutions for CRISPR Genome Engineering. Synthego provides customized engineered cells and CRISPR kits. They are in turn enabling researchers to gain access to CRISPR. Thus, speeding up the progress of genetic engineering and CRISPR development. The company’s flagship product, CRISPRevolution, is a portfolio of synthetic RNA designed for CRISPR genome editing and research.

Synthego’s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.

Synthego customers include leading institutions in over 30 countries around the world and 9 of the top 10 global biology universities.

9. Beam Therapeutics

Beam Therapeutics

  • Total Funding: $222M
  • Year Founded: 2017
  • Headquarters: Cambridge, Massachusetts, USA.
  • Founders: David R. Li, Feng Zhang, J.Keith Joung, John Evans
  • Targeted Areas: Genetics, Medical, Therapeutics

Beam Therapeutics is pioneering the use of CRISPR base editing to generate a pipeline of precision genetic medicines that treat disease. The Company works on technologies that repair disease-causing point mutations and make edits to individual base pairs in the genetic code.

10. Inscripta


  • Total funding: 134.5M
  • Year founded: 2015
  • Headquarters: Boulder, Colorado, USA.
  • Founders: Andrew Garst, Ryan T Gill, Tanya Lipscomb
  • Target Areas: Biotechnology, Healthcare

Inscripta engages in developing a family of CRISPR enzymes, MADzymes, custom nucleases for researchers and commercial partners. Moreover, the Company also creates a full suite of gene editing tools, including software, instruments, and reagents that increase the speed and efficiency of precision gene editing.

Explore More: Why Bill Gates is Investing in Biotech Companies


Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.